HAC (Russian)
RSCI (Russian)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services


Download full text PDF

N. Komleva (1), MD; Professor A. Maryanovsky (2), MD; Associate Professor A. Danilov (1), Candidate of Medical Sciences; I. Zaikina (1), Candidate of Medical Sciences 1 -Saratov Research Institute for Agricultural Hygiene, Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfare 2 -N.I. Pirogov Russian National Research Medical University, Moscow

The paper gives the results of an open-label longitudinal randomized study, which suggest that is expedient to incorporate the antihomotoxic agents Spascupreel and Mucosa compositum into combination therapy for patients with gastroesophageal reflux disease; the drugs regress the symptoms of the disease, increase the period of remission, and improve the results of endoscopic studies and the indicators of quality of life.

gastroesophageal reflux disease
antihomotoxic agents
bioregulatory drugs
Spascupreel and Mucosa compositum

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

  1. Bashashati M., Hejazi R., Andrews C. et al. Gastroesophageal reflux symptoms not responding to proton pump inhibitor: GERD, NERD, NARD, esophageal hypersensitivity or dyspepsia? // Can. J. Gastroenterol. Hepatol. – 2014; 28 (6): 335–41.
  2. Bruley des Varannes S., Cestari R., Usova L. et al. Classification of adults suffering from typical gastroesophageal reflux disease symptoms: contribution of latent class analysis in a European observational study // BMC Gastroenterol. – 2014; 14: 112.
  3. El-Serag H., Sweet S., Winchester C. et al. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review // Gut. – 2014; 63 (6): 871–80.
  4. Mason J., Hungin A. Review article: gastro-oesophageal reflux disease – the health economic implications // Aliment. Pharmacol. Ther. – 2005; 22 (1): 20–31.
  5. Tack J., Becher A., Mulligan C. Systematic review: the burden of disruptive gastro-oesophageal reflux disease on health-related quality of life // Aliment. Pharmacol. Ther. – 2012; 35 (11): 1257–66.
  6. Nwokediuko S. Current trends in the management of gastroesophageal reflux disease: a review // ISRN Gastroenterol. – 2012; ID391631.
  7. Boeckxstaens G., El-Serag H., Smout A. et al. Symptomatic reflux disease: the present, the past and the future // Gut. – 2014; 63 (7): 1185–93.
  8. Subramanian C., Triadafilopoulos G. Refractory gastroesophageal reflux disease // Gastroenterol. Rep. – 2015; 3 (1): 41–53.
  9. Bueno L., Lafforgue G., Beaufrand C. et al. Colonic and anorectal disorders targeting the IBS pathophysiology in stressed rats using a multicomponent HE-400 // J. Gastroenterol. Hepatol. – 2013; 28 (suppl. 3): 347–8.
  10. Komleva N.E., Spirin V.F., Zaikina I.V. Izuchenie effektivnosti antigomotoksicheskoj terapii GERB // Mezhdunarodnyj zhurnal prikladnyh i fundamental'nyh issledovanij. – 2015; 8–1: 52–4.
  11. Lundell L., Dent J., Bennett J. et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angelesclassification // Gut. – 1999; 45 (2): 172–80.
  12. Ware J. SF-36 Health Survey Update // Spine. – 2000; 25: 3130–9.
  13. Novik A.A., Ionova T.I. Rukovodstvo po issledovaniju kachestva zhizni v meditsine / SPb: Neva, 2002; 320.